Study Stopped
No More recruitment surgeon left the team
Perioperative Analgesia by ESP Catheter on Paediatric Recipient for Liver Transplantation
ESPLIVPAED
Does Bilateral Continuous Peri Operative Erector Spinae Plane (ESP) Block Improve Analgesia and Reduce Opioid Consumption for Liver Transplantation in Recipient Paediatric Patient
1 other identifier
interventional
12
1 country
1
Brief Summary
Pediatric Liver transplantation surgery is associated with moderate to severe postoperative pain that is related to large abdominal incision cutting muscles and fascia and the anterior abdominal wall and drains. Peri-operative pain management after this surgery is centered on intravenous opioids, which cannot provide complete pain relief and are responsible for side effects such as vomiting or respiratory depression. Fifty-two per cent of pediatric patients reported moderate to severe pain on the day of surgery and 33% on day 1. 42% of patients reported vomiting. Increasing interest has focused on opioid sparing analgesic strategies to avoid some of the detrimental side effects of opioids. Recently, the focus has been on postoperative regional analgesia after major pediatric in major thoracic or abdominal surgeries. Thoracic epidural anesthesia or paravertebral blocks are efficacious but raise some concerns related to their potential complications especially in Liver transplantation with the risk of coagulation disorders. Erector spinae plane block (ESPB) is an interfascial plane block whereby Local anesthestic (LA) is injected beneath the iliocostalis, longissimus, and spinalis muscles to achieve multi metameric analgesia for pediatric thoracic, cardiac, or abdominal surgery. I Investigators' hypothesis is with efficient peri operative regional analgesia will reduce the opioids consumption, allow a very early extubation after such long surgeries and improve the quality of recovery by reducing the side effects of opioids as sedation. nausea vomiting delay of first intake.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2021
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 1, 2021
CompletedFirst Posted
Study publicly available on registry
April 9, 2021
CompletedStudy Start
First participant enrolled
June 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 14, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
August 14, 2023
CompletedAugust 21, 2023
August 1, 2023
2.2 years
April 1, 2021
August 15, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
peri operative Opioids consumption
Dose of opioids used
up to day 7 after the end of surgery
Secondary Outcomes (5)
Time to extubate
up to 6 hours after the end of the surgery
Duration of stay in Intensive care Unit (ICU)
up to 72 hours after the end of the surgery
Length of stay in hospital
up to 30 day after the end of the surgery
first intake
up to 72hours after the end of the surgery
first mobilisation
up to 72hours after the end of the surgery
Study Arms (2)
Standard of cares
NO INTERVENTIONPeri operative analgesia by opioids
regional analgesia
EXPERIMENTALPeri operative analgesia by continuous bilateral ESP catheters
Interventions
Peri operative regional analgesia by bilateral ESP catheter for 72h
Eligibility Criteria
You may qualify if:
- Recipient liver transplantation who accepted to participate ( parents or guardians)
You may not qualify if:
- Refusal participation.
- Allergy to LA
- Intubated ventilated pre-operation
- Severe coagulation disorder
- Coma
- Prediction of large volume liver implanted
- After surgery performed Large volume implanted with a need of post operative controlled ventilation
- After surgery performed Organ failure
- After surgery performed Unstable patient
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
VinMec International hospital
Hanoi, Vietnam
Study Officials
- PRINCIPAL INVESTIGATOR
philippe Macaire, MD
VinMEC
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 1, 2021
First Posted
April 9, 2021
Study Start
June 1, 2021
Primary Completion
August 14, 2023
Study Completion
August 14, 2023
Last Updated
August 21, 2023
Record last verified: 2023-08
Data Sharing
- IPD Sharing
- Will not share